Abstract:Background: Ventricular septal defect (VSD) is the most common congenital cardiac malformation, accounting for approximately 30% of congenital heart defects. Conventional surgical repair using cardiopulmonary bypass is invasive and associated with morbidities and prolonged hospital stay. With the advent of interventional approaches and availability of different occluding devices, the technique of perventricular device closure is evolving and being implemented successfully in larger groups of patients. We present herein, our initial experience of perventricular device closure for the ventricular septal defects in children to assess risks and benefits. Methods: From March, 2023 to February, 2024, we have performed perventricular closure of ventricular septal defects in 13 children, under guidance of transesophageal echocardiography without cardiopulmonary bypass support. The median age at operation was 2 year (range 1.3-10 years) with the median body weight 11 kg (range 8.7-16.6 kg). Sixty-nine percent were males. The ventricular septal defect sizes ranged from 2.7 to 6 mm (mean 4.7 mm). Seven defects were perimembranous, four sub-aortic and two were muscular. One patient also underwent pulmonary artery de-banding with pulmonary artery balloon angioplasty and other one patent ductus arteriosus ligation, concomitantly. For defect closure, we used ventricular septal defect occlusion device (MemoPart™, Lepu Medical Technology Company, China) through a 3-cm skin incision in the lower- third of the sternum. The device sizes ranged from 5 to 8 mm (mean 6.9+-1.8 mm) and all patients except for two required symmetrical devices. Results: All patients underwent device closure successfully. The procedural duration ranged between 32 and 52 min. None of the patients required cardiopulmonary bypass. The mean ventilation time and intensive care unit stay was 3 and 24 h, respectively. None of the patients required inotropic support or blood transfusions. Moreover, no patients developed any arrhythmias including heart block. The average length of hospital stay was 4.4 days. At the latest follow up, there were no residual shunts, conduction disturbances, device dislodgement or major aortic or tricuspid valve complications seen in any patients. There was no mortality. Conclusions: Perventricular device closure of ventricular septal defects is a less invasive, extremely safe and effective method in children. It is associated with very fast recovery, shorter hospitalization time and better cosmetic incision. Moreover, it avoids cardiopulmonary bypass. The modifications and refinements in the design, material and implantation techniques will help in expanding the indications and prevent complications in the long-term.

Feasibility and Success of Muscular Ventricular Septal Defect Occluders and Mushroom-Shaped Occluders in Transcatheter Patent Ductus Arteriosus Closure in Low-Weight Children: A Propensity Score-Matched Retrospective Analysis from a Chinese National Regional Health Center

Perimembranous Ventricular Septal Defect Closure Via Ultra-Minimal Trans Intercostal Incision in Children.

Doubly Committed Ventricular Septal Defect Closure Using Eccentric Occluder Via Ultraminimal Incision

Treatment of Patent Ductus Arteriosus and Short-Term Outcomes among Extremely Preterm Infants: a Multicentre Cohort Study

A Study on Eccentric Occluder Via Ultra Minimal Incision of Doubly Committed Subarterial Ventricular Septal Defects

Minimally Invasive Perventricular Device Closure of Perimembranous Ventricular Septal Defect Without Cardiopulmonary Bypass: Multicenter Experience and Mid-Term Follow-Up

Perimembranous Ventricular Septal Defect Performed Super Minimally Invasive Trans Intercostal Device Closure under the Guidance of Transesophageal Echocardiography in Children

ASSA14-14-04 Transcatheter Closure of Patent Ductus Arteriosus in Children with Body Weight ≤ 8 Kg

Procedural Efficiencies and Clinical Outcomes for Transcatheter Device Closure of Perimembranous Ventricular Septal Defects With Different Waist-Length Occluders

Perventricular device closure of the ventricular septal defects in children-first experience in the United Arab Emirates

Clinical evaluation of catheter closure of patent ductus arteriosus by Chinese-made mushroom-shape occluder in adults

Catheter closure of patent ductus arteriosus with pulmonary hypertension by domestic-made mushroom occluder in adults

Transcatheter closure of congenital perimembranous ventricular septal defect in children using symmetric occluders: an 8-year multiinstitutional experience.

Clinical evaluation of transcatheter closure of PDA with different type of devices

Safety of an improved patent ductus arteriosus occluder for transcatheter closure of perimembranous ventricular septal defects with abnormally attached tricuspid chordae tendineae.

Value of Transesophageal Echocardiography in Device Closure of Perimembranous Ventricular Septal Defects in Children Via Ultra‐minimal Trans Intercostal Incision

Transcatheter and Surgical Ductus Arteriosus Closure in Very Low Birth Weight Infants: 2018-2022

Safety, effectiveness, and complications of the first-in-human minimally invasive transthoracic ventricular septal defect closure using a bioabsorbable occluder: a cohort study with 12-month follow-up

Catheter closure of patent ductus arteriosus by mushroom shape occluder in infants

Post-ligation cardiac syndrome after surgical versus transcatheter closure of patent ductus arteriosus in low body weight premature infants: a multicenter retrospective cohort study

Clinical Study on Application of Amplatzer Duct Occlude-ⅱ to Occlude Patent Ductus Arteriosus